CYT006-AngQb
Vaccine description | |
---|---|
Target disease | Hypertension |
Type | Conjugate vaccine |
Clinical data | |
Routes of administration | Subcutaneous |
Legal status | |
Legal status |
|
Identifiers | |
ATC code | none |
CYT006-AngQb is an investigational vaccine against angiotensin II, designed to lower blood pressure.
Method of action
Angiotensin II causes blood vessels to constrict, and drives blood pressure up. CYT006-AngQb consists of virus-like particles covalently coupled to angiotensin II. Subcutaneous injection causes the immune system to produce antibodies which reduce angiotensin II blood levels, lowering blood pressure.
Studies
In a 2008 phase IIa study, 72 patients received 100 µg, 300 µg or placebo in weeks 0, 4, and 12. Blood pressure was lowered dose-dependently, by 5.6 mmHg (systolic) and 2.8 mmHg (diastolic) in the 300 µg group. Morning blood pressure (8:00) was lowered by 25 mmHg (systolic) and 13 mmHg (diastolic).
Side effects were mild and included local reactions, headache and fatigue.[1]
The 2008 trial was small and exploratory. It did not address the question of whether the vaccine actually protects internal organs, nor did it address safety concerns such as whether the vaccine would cause autoimmune disease. If a standard drug treatment is found to dangerously inhibit the renin-angiotensin-aldosterone system, it can be withdrawn and the effects reversed quickly, but that would not be true of the vaccine. However, poor compliance to standard treatment is the main reason for inadequate control of blood pressure, and if vaccination were safe and effective in the long run, it may solve many compliance problems.[2]
As of November 2008[update], two new phase II studies are recruiting patients to evaluate safety and efficacy of this vaccine.[3][4]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
40px | This antihypertensive-related article is a stub. You can help ssf by expanding it. |
- ↑ Tissot AC, Maurer P, Nussberger J; et al. (2008). "Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study". Lancet. 371 (9615): 821–7. doi:10.1016/S0140-6736(08)60381-5. PMID 18328929.
- ↑ Samuelsson O, Herlitz H (2008). "Vaccination against high blood pressure: a new strategy". Lancet. 371 (9615): 788–9. doi:10.1016/S0140-6736(08)60355-4. PMID 18328909.
- ↑ Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
- ↑ Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
- Pages with script errors
- Drugs that are a vaccine
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from November 2008
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- Vaccines
- Antihypertensive agents
- Pages with broken file links
- Antihypertensive agent stubs
- 2Fix
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list